BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

NCT06746519 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine

Sponsor

Chen Suning

Collaborators

[object Object]